Organogenesis Holdings (ORGO) Free Cash Flow Growth (3y) (2019 - 2026)
Organogenesis Holdings (ORGO) Free Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 39.19% |
| 10 | Organogenesis Holdings | 323.97 Mn | 231.87 Mn | 11.46 Mn | 65.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.65% |
| Dec 31, 2025 | 142.01% |
| Sep 30, 2025 | 29.48% |
| Jun 30, 2025 | -261.01% |
| Mar 31, 2025 | -271.91% |
| Dec 31, 2024 | -15.87% |
| Sep 30, 2024 | -18.09% |
| Jun 30, 2024 | -52.35% |
| Mar 31, 2024 | -20.50% |
| Dec 31, 2023 | -25.73% |
| Sep 30, 2023 | -40.99% |
| Jun 30, 2023 | 40.28% |
| Mar 31, 2023 | 31.03% |
| Dec 31, 2022 | 33.83% |
| Sep 30, 2022 | 9.73% |
| Jun 30, 2022 | 60.97% |
| Mar 31, 2022 | 64.07% |
| Dec 31, 2021 | 40.79% |
| Sep 30, 2021 | 35.10% |
| Jun 30, 2021 | 41.08% |